Jci_page_head_homepage_01 Jci_page_head_homepage_02
Rosa Bacchetta, Laura Passerini, Eleonora Gambineri, Minyue Dai, Sarah E. Allan, Lucia Perroni, Franca Dagna-Bricarelli, Claudia Sartirana, Susanne Matthes-Martin, Anita Lawitschka, Chiara Azzari, Steven F. Ziegler, Megan K. Levings, Maria Grazia Roncarolo
Published in Volume 116, Issue 6
J Clin Invest. 2006; 116(6):1713–1722 doi:10.1172/JCI25112
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 4
Suppressive activity of patients’ CD4+ CD25high T cells.

The ability of freshly isolated CD4+CD25high T cells of patient 2, patient 2bis, patient 3, and NDs to suppress either ND CD4+CD25 effector T cells or autologous CD4+CD25 effector T cells was assessed (in the case of NDs, effector and suppressor cells were derived from the same individuals). Responder cells were activated either in the presence of 50,000 irradiated (60 Gy) APCs plus soluble anti-CD3 mAb (1 μg/ml) (A) or with anti-CD3 plus anti-CD28 mAb–coated beads (B) (see Methods for details). CD4+CD25high T cells (Treg) were added to activated responder cells (R), and [3H]thymidine incorporation was measured after 72 hours. Percentages indicate inhibition of proliferation.